1. AstraZeneca and Amgen get optimistic phase 3 asthma drug results — Pfizer/BioNTech begin studies for third booster dose and development of vaccine for variants — Merck KGaA in biobucks pact with Debiopharm for next-gen cancer asset See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice

spine 3-5 yrs

Discussion in 'NuVasive' started by Anonymous, Feb 24, 2011 at 9:46 PM.

  1. Anonymous

    Anonymous Guest

    In the near future (3-5 years from now) what Spine company would you want to work for and why? just curious to where the reps think the grass will be the greenest...
     
  2. Anonymous

    Anonymous Guest

    Zimmer Spine to open the door to Recon. Spine market has slowed down except for a few technologies.
     
  3. Anonymous

    Anonymous Guest

    No secret if you stay current on info. With healthcare reform and pricing pressures, only the large well diversified companies will be left standing. MDT, Stryker, JJ and whoever else gets bought. Spine only companies like Globus, Nuva will need to make strategic moves to compete. They will still be around but vendor consolidation in hospitals will keep the MDT around. They have pacemakers, spine, drills, endo, ent. JJ as well. If a hospital had a choice in limiting vendors, who will they pick, MDT or Globus. The writing is on the wall. MDT will be around but no one will be making top dollar anymore. 7 points on a $400 screw. Pharma like money.